HomeNewsCIS, Clinically Isolated Syndrome, ms, multiple sclerosisProgression from CIS to MS to be predicted by Peripheral blood cells, research finds

Progression from CIS to MS to be predicted by Peripheral blood cells, research finds

  • May 16, 2018
  • Posted by: PharmaScroll
  • Category:
No Comments

images (2)

  • CIS patients that convert to MS in three years display higher effector B cell frequencies.
  • CIS patients that do not convert to MS have lower effector B cell frequencies.
  • Excess activation or inability to suppress effector B cells might lead to MS conversion.

As per a recent research study published in Multiple Sclerosis and Related Disorders Journal, Peripheral blood memory B cell frequency can predict conversion from clinically isolated syndrome to multiple sclerosis in patients.

Starting from the first attack, activated B cells are found in multiple sclerosis (MS) patients and are associated with disease activity. In the study, Peripheral blood cells of 17 clinically isolated syndrome (CIS) patients were collected during the first attack. CIS patients were divided as those converting to MS (CIS-MS+, n = 8) and not converting to MS (CIS-MS-, n = 9) in three years. Age-gender matched MS patients (n = 19) and healthy individuals (n = 20) were included as controls. Peripheral blood frequencies of total, immature, naive, unswitched and switched memory B cells, plasmablasts and plasma cells were measured by flow cytometry.

Results of the study:

CIS patients showed reduced unswitched memory B cell and plasma cell frequencies. CIS-MS- patients had significantly increased levels of total B cells and suppressed unswitched memory B cell and plasma cell frequencies.

The study concluded that the results suggest that conversion from CIS to MS occurs due to the inability of the immune system to suppress effector B cell production.

 

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Multiple Sclerosis, visit https://pharmascroll.com/news-category/multiple-sclerosis/

 

News Source: https://www.msard-journal.com/article/S2211-0348(18)30134-2/fulltext

Image Source: https://www.healthline.com/health-news/biomarkers-future-of-multiple-sclerosis-treatment